KDM5D and neoplasm: KRAS–STAT4 pathway targets a Y chromosome gene KDM5D, which inhibits the expression of tight junction proteins angiomotin (AMOT) and MHC-I through epigenetic regulation, ultimately driving tumor metastasis and immune escape in a male-specific manner [117].